A Phase 1/2 interventional study of umbilical cord mesenchymal stem cells in Diabetes Mellitus, Diabetes Mellitus, Type 1 and Mesenchymal Stem Cells, sponsored by Qingdao University. Status unknown at 1 site in China. Open to participants aged 3 Years to 35 Years. Per ClinicalTrials.gov, last updated 2010-10-13.
Sponsored by Qingdao University · Phase 1/2, Interventional, and Treatment
The purpose of this study is to determine whether umbilical cord Mesenchymal Stem Cells of treatment for initial type 1 diabetes is safe and effective.
Type 1 diabetes mellitus (T1DM)is characterized by the autoimmune destruction of the pancreatic β cells.Patients require multiple daily insulin injections throughout their lives as well as close monitoring of their diet and blood sugar levels to prevent complications. The investigators hope umbilical cord Mesenchymal Stem Cells could not only address the need for β-cell replacement but also control of the autoimmune response to β cells.
10,925 studies on the registry are indexed under Diabetes Mellitus; 1,318 are open to participants now.
This study's planned enrollment of 50 is below the median of 80 across 8,367 interventional studies indexed under Diabetes Mellitus.
Browse Diabetes Mellitus studies →Qingdao University is the lead sponsor of 22 studies on the registry; 4 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Intravenous infusion of ex vivo cultured umbilical cord mesenchymal stem cells
Biological: umbilical cord mesenchymal stem cells
Transfusion of the umbilical cord mesenchymal stem cells (2 x 107 cells) intravenously.
Also known as: mesenchymal stem cells
C peptide release test
Time frame: 3 months
Exogenous insulin dose
Time frame: 3 months
blood glucose
Time frame: 3 months
glycosylated Hemoglobin A1c
Time frame: 3 months
Number of severe and documented hypoglycemic events
Time frame: 3 months
Immunologic reconstitution parameters
Time frame: 3 months
This study is status unknown, as verified in Sep 2010. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Qingdao University